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1  | INTRODUC TION
Malaria caused by Plasmodium falciparum is a leading killer of infants 
and children. Efforts to develop a protective vaccine have been hin‐
dered by the parasite's numerous evasion strategies, which include 
the induction of immunoregulatory mechanisms in the human host. 
Indeed, several promising vaccine candidates that induce robust 
protection in malaria‐naive populations have been shown to have 
much lower efficacy when administered to individuals residing in en‐
demic settings,1,2 suggesting that immunomodulatory mechanisms 
induced by prior malaria exposure may pose a critical barrier to 
vaccine‐mediated protection. In endemic regions, many individuals 
are first exposed to malaria in utero, when P. falciparum‐infected red 
blood cells sequester in the placenta and parasite antigens cross the 
syncytiotrophoblast barrier, gaining entry into the fetal circulation. 
Therefore, even during the neonatal period, vaccination may be in‐
fluenced by prior malaria exposure. Here, we examine the conse‐
quences of in utero antigen exposure for fetal immune development 
and postnatal immunity.
The worldwide burden posed by malaria‐related complications of 
pregnancy is profound. More than 125 million pregnancies occur an‐
nually in regions at risk for malaria transmission,3 and one in four preg‐
nant women in sub‐Saharan Africa have evidence of infection with 
malaria at parturition.4 Although most placental malaria (PM) infec‐
tions are attributable to P. falciparum, recent evidence indicates that P. 
vivax is also associated with poor pregnancy outcomes, and some data 
suggest that it too may sequester in the placenta.5,6 Pregnancy‐associ‐
ated malaria results in tremendous obstetrical and pediatric morbidity, 
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Abstract
Malaria causes tremendous early childhood morbidity and mortality, providing an ur‐
gent impetus for the development of a vaccine that is effective in neonates. However, 
the infant immune response to malaria may be influenced by events that occur well 
before birth. Placental malaria infection complicates one quarter of all pregnancies 
in Africa and frequently results in exposure of the fetus to malaria antigens in utero, 
while the immune system is still developing. Some data suggest that in utero exposure 
to malaria may induce immunologic tolerance that interferes with the development 
of protective immunity during childhood. More recently, however, a growing body of 
evidence suggests that fetal malaria exposure can prime highly functional malaria‐
specific T‐ and B‐cells, which may contribute to postnatal protection from malaria. In 
utero exposure to malaria also impacts the activation and maturation of fetal antigen 
presenting cells and innate lymphocytes, which could have implications for global im‐
munity in the infant. Here, we review recent advances in our understanding of how 
various components of the fetal immune system are altered by in utero exposure to 
malaria, discuss factors that may tilt the critical balance between tolerance and adap‐
tive immunity, and consider the implications of these findings for malaria prevention 
strategies.
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including maternal anemia, intrauterine growth retardation, low birth 
weight, prematurity, miscarriage, and stillbirth, and it has been esti‐
mated to contribute to 100 000 infant deaths per year.4 While the ob‐
stetric complications of PM have been studied extensively, it remains 
unclear whether prenatal exposure to malaria has a lasting detrimental 
impact on the infant. Notably, several observational studies have re‐
ported that infants born to women with PM are themselves at higher 
risk of malaria during early life,7‐14 and may even have increased vul‐
nerability to non‐malarial febrile illnesses.15
In this review, we summarize recent advances in our understanding 
of how the fetal immune system responds to malaria antigens encoun‐
tered as a result of P. falciparum infection during pregnancy. A number 
of recent studies have shed light on how the infant's immune response 
is shaped by malaria antigen exposure during fetal life. Some evidence 
suggests that in utero malaria exposure results in the development 
of tolerance, which could contribute to poor immunity to malaria in 
early life.11,16,17 However, other recent studies have found evidence 
that the fetus, even before birth, mounts a functional adaptive im‐
mune response to malaria antigens that may protect against postnatal 
infection.18‐21 We will highlight knowledge gaps in our understand‐
ing of human fetal immune ontogeny, the functional competence of 
fetal T‐cells and antigen‐presenting cells (APCs), and factors governing 
effector vs regulatory T‐cell differentiation in utero. Finally, we will con‐
sider the implications of these findings for the development of immu‐
nity to malaria and other pathogens during childhood, and how malaria 
control interventions may—favorably or adversely—impact this process.
2  | MAL ARIA IN PREGNANCY
To understand how maternal infection with P. falciparum may im‐
pact the infant in utero and beyond, it is important to consider the 
immunopathologic mechanisms by which malaria parasites invade, 
sequester, and induce local inflammation in the placenta, and how 
the timing of these events intersects with critical junctures in fetal 
immune development (Figure 1). Here, we discuss the biology of PM, 
as well as host factors associated with increased vulnerability to PM 
and potential avenues for intervention and prevention.
2.1 | The biology and histopathology of 
placental malaria
Placental malaria occurs when P. falciparum‐infected erythrocytes 
adhere to placental receptors and sequester within the intervillous 
F I G U R E  1   Developmental changes in the placenta and fetal immune system during gestation. Maternal blood first enters the intervillous 
space at 8‐9 wks gestation, enabling Plasmodium falciparum‐infected red blood cells to contact the placenta. This is followed by progressive 
loss of the cytotrophoblast layer beginning at week 14, leaving the fused syncytiotrophoblast (STB) layer as the sole barrier between 
maternal and fetal blood. At 13‐16 wks gestation, STB cells begin expressing FcRn, which transports IgG and immune complexed antigens 
across the placenta. Transplacental transfer of IgG increases exponentially until term. Meanwhile, T‐cells are evident in the fetus as early as 
week 10 of gestation, thymic architecture is mature at week 14, and the splenic T zone is evident at week 18. Fetal Foxp3+ CD4 Tregs and 
γδ T‐cells are most abundant in the fetus at mid‐gestation, but decline progressively between weeks 20‐40
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spaces of the placenta. The presence of infected erythrocytes stim‐
ulates maternal mononuclear cells to secrete β‐chemokines that 
are chemotactic for maternal monocytes and macrophages (MIP1α, 
MIP1β, IP10, and MCP1), resulting in variable degrees of inflamma‐
tion. Histologically, PM is characterized by breakdown of syncytio‐
trophoblast layer, with focal denudement; infiltration of maternal 
monocytes; sequestration of parasitized erythrocytes; and deposi‐
tion of hemozoin and other erythrocyte breakdown products that 
are themselves toxic and inflammatory.22 Rogerson et al proposed 
three histologic categories of PM: “active‐acute” in which parasites 
are detected but there is minimal or no deposition of pigment or 
fibrin; “active‐chronic” in which both parasites and substantial pig‐
ment and perivillous fibrin are seen; and “past” or resolved infection 
in which pigment is observed, but no parasites are detected.23 Of 
note, this categorization does not consider the degree of placental 
inflammation, which, along with the chronicity of infection has been 
found to correlate with the risk of fetal growth restriction.23,24
2.2 | Risk factors and timing of placental infection
The risk of malaria is higher in pregnant women than in non‐pregnant 
adults, and even women who have acquired substantial immunity 
to malaria following repeated life‐long exposure become suscepti‐
ble again once pregnant. Among pregnant women, primagravidity 
is the strongest host risk factor for PM. The decline in the risk of 
PM in subsequent pregnancies is believed to be due to the acqui‐
sition of antibodies that block the adhesion of parasitized RBCs to 
chondroitin sulfate A and other adhesion molecules expressed in 
the placenta,22 as recently reviewed by Fried et al25 The conserved 
parasite gene var2csa encodes a pregnancy‐specific adhesion ligand 
that is thought to be an important mediator of placental adherence. 
In some studies, antibodies against var2csa have been shown to cor‐
relate with protection from PM, and this antigen is now the target 
of a major PM vaccine development effort.25 There are, however, 
additional gravidity‐associated differences in the immunology of the 
fetal‐maternal interface, including activation of macrophages and 
“trained memory” of uterine NK cells, which could also theoretically 
contribute to the reduced risk of PM infection seen in multigravid 
women.26,27
The earliest window of vulnerability to PM has not been defini‐
tively established. It is known that the placenta can become infected 
by 9‐12 weeks gestation and perhaps even earlier, when maternal 
blood first enters the intervillous space and begins to perfuse the 
placenta at 8‐9 weeks gestation.28‐30 A recent modeling study used 
placental histopathology results, parity, and transmission intensity 
data to estimate that 63% of infections become established by the 
end of the first trimester, with the highest risk occurring at the end 
of the third month.31 The risk of PM correlates with the frequency 
and parasite density of maternal P. falciparum infections during preg‐
nancy, but even low‐density infections (ie those that are detectable 
by sensitive PCR or LAMP tests but not blood smear) can result in 
placental infection.32 Importantly, many maternal infections that re‐
sult in PM are clinically silent.33,34 This poses a barrier to accurate 
determination of the timing of infection, as well as a practical imped‐
iment to treatment and prevention strategies.
2.3 | Strategies for prevention of placental malaria
In low resource settings, antenatal care is often not established until 
after “quickening,” the onset of perceptible fetal movements, which 
typically occurs at 13‐20 weeks gestation. Primagravidas, who are at 
highest risk for PM, tend to experience quickening later in gestation 
than multigravidas. Thus, PM infection is often already established 
by the time a woman presents for prenatal care, making interven‐
tion challenging.5,34 Currently, WHO recommends intermittent pre‐
sumptive treatment (IPTp) of pregnant women in malaria‐endemic 
regions with sulfadoxine‐pyrimethamine (SP), which is to be given 
at least three times during pregnancy. However, the efficacy of SP is 
limited by the fact that in some regions, particularly East Africa, an‐
tifolate resistance is nearly universal among circulating P. falciparum 
strains. To address this, recent trials have tested the efficacy of other 
antimalarial drugs, such as dihydroartemisinin‐piperaquine (DP), for 
use as IPTp.35,36 DP is an artemisinin combination therapy (ACT) that 
combines the rapid killing of dihydroartemisinin with a prolonged 
postadministration prophylactic effect due to the long half‐life 
of piperaquine, such that monthly administration provides nearly 
continuous prophylaxis against reinfection. In a study conducted 
in Uganda, Kakuru et al found that DP had superior efficacy to SP 
in preventing maternal parasitemia, symptomatic malaria, and PM, 
and when given monthly DP reduced the rate of adverse birth out‐
comes.35 DP therefore represents an attractive alternative for IPTp 
in areas of high antifolate resistance. However, the long‐term utility 
of the artemisinin drug class for IPTp is threatened by the emergence 
of artemisinin‐resistant P. falciparum strains, which are now increas‐
ingly prevalent in Southeast Asia.37 Moreover, regardless of the an‐
timalarial drug used, the efficacy of IPTp as a strategy is limited by 
the fact that vulnerability to PM begins in the first trimester, when 
few women are enrolled in prenatal care. Concerns for teratogenic‐
ity further limit antimalarial drug options in the first trimester. For all 
of these reasons, alternate strategies, including maternal vaccination 
and vector control approaches, will likely be needed to reduce the 
risk of placental infection in early pregnancy.
3  | MAL ARIA ANTIGEN E XPOSURE IN 
UTERO
True congenital malaria—in which intact parasites cross into the fetal 
circulation and establish a self‐propagating blood stage infection—
has been clearly documented, but it is rare.38 Nonetheless, several 
lines of evidence indicate that malaria antigens gain access to the 
fetal circulation after crossing the placenta.39‐42 Exactly how they 
do this is not entirely clear. The placenta is an effective physical 
barrier that protects the fetus against many pathogens (Figure 2).43 
The syncytiotrophoblast layer, comprised of fused multinucleated 
cells that line the chorionic villi and directly contact maternal blood, 
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lacks intercellular junctions and has a dense actin cytoskeleton net‐
work that confers elasticity and contributes to its physical barrier 
function.44,45 Direct contact between maternal blood and syncy‐
tiotrophoblasts does not occur until the end of the first trimester, 
when the extra‐villous trophoblast plug erodes, allowing maternal 
blood to flood the intervillous space. During the first trimester, a 
second cell layer comprised of cytotrophoblasts underlies the syn‐
cytiotrophoblast layer, but this degenerates as the placenta grows, 
leaving only the single syncytiotrophoblast layer separating the ma‐
ternal and fetal blood.28 While low molecular weight compounds 
(<500 Da) can simply diffuse across this placental barrier, larger com‐
pounds are generally prevented from traversing an intact placenta 
in the absence of an active transport mechanism.46 At least some 
malaria antigens appear to be transported across the placenta as im‐
mune complexes,19,39 which are ferried across the syncytiotropho‐
blast cell layer by FcRn, the neonatal Fc receptor. FcRn is expressed 
by syncytiotrophoblast cells and acts as a pH‐dependent shuttle. 
Syncytiotrophoblast cells also express FcγRIIIa, which may play a 
role in antigen uptake from the intervillous space.28,47 In addition to 
receptor‐mediated transport, malaria antigens may access the fetal 
circulation more directly, as inflammatory PM can cause disruption 
of placental barrier function, including focal denudement and ne‐
crosis of the syncytiotrophoblast layer,22 bringing the stromal core 
of villi in direct contact with maternal blood. This may permit larger 
molecules or even cells to enter into the fetal circulation.42,48 Once 
across the syncytiotrophoblast barrier, it is unclear how exogenous 
antigens traverse the fetal endothelium, which represents the last 
barrier to entry into the fetal bloodstream, although FcgRI on en‐
dothelial cells could play a role. Presumably, malaria antigens and/
or immune complexes are subsequently taken up by fetal APCs, al‐
though this process has received little or no research attention. Fetal 
macrophages termed Hofbauer cells reside within the villous stroma 
and are increased in PM, but their functional role has not been well 
characterized.49 Two key distinctions between transplacental expo‐
sure to malaria antigens and that which occurs with natural malaria 
are that the fetus is exposed only to blood stage antigens (as pre‐
erythrocytic stage parasites are not present in the placenta), and 
fetal exposure is likely of “low dose,” contrasting with the extremely 
high antigen burden characteristic of malaria.
In addition to malaria antigens, PM may result in exposure of 
the fetus to cytokines, microbial products and metabolites, and 
other inflammatory mediators that could impact the fetal immune 
system. Placental perfusion studies indicate that cytokines them‐
selves generally cannot cross the term placenta,50 although their 
levels are often similar between maternal and cord blood at deliv‐
ery, suggesting that there may be some coordinate regulation.51 
Syncytiotrophoblast cells themselves produce type III interferons 
and chemokines.28 Local inflammation in the placenta recruits ma‐
ternal macrophages, monocytes, and lymphocytes and leads to their 
activation, and such inflammation is associated with placental insuf‐
ficiency even in the absence of direct pathogen invasion. Perhaps 
the most critical consequence of inflammation at the fetal‐maternal 
interface is an increase in the risk of preterm birth, a key complica‐
tion of PM.5,52 In women with PM, levels of cytokines and chemo‐
kines including CXCL9, IFNγ, IL‐10, and IL‐1β have been associated 
with poor pregnancy outcomes including fetal loss, low birthweight, 
and preterm delivery.53 It is likely that transfer of immune‐modulat‐
ing factors into the fetal circulation may have additional, currently 
unknown, influences on fetal immune development.
The gestational timing of in utero antigen exposure may play a large 
role in determining its impact on fetal immunity. In individual cases, it 
is not usually possible to discern the timing of fetal malaria exposure 
using non‐invasive testing methods. In clinical trials, a variety of diag‐
nostic methods, varying in sensitivity, have been used to define PM. 
These include histopathologic examination of the placenta and test‐
ing of placental intervillous blood obtained at delivery by blood smear, 
F I G U R E  2   The maternal‐fetal interface and potential routes of antigen transfer. A, Anatomically, the human placenta is comprised 
of tree‐like chorionic villi that directly contact maternal blood in the intervillous space. B, Chorionic villi are lined by a single layer of 
multinucleated syncytiotrophoblast (STB) cells. Plasmodium falciparum‐infected red blood cells (iRBCs) adhere to syncytiotrophoblasts, and 
attract inflammatory mediators which may lead to focal STB denudement (dotted line). This disruption of the STB barrier may cause free 
malaria antigens to contact the villous stroma, which is patrolled by fetal Hofbauer cells (Hof). C, FcRn mediates transfer of IgG, and possibly 
immune complexes, across the STB layer to the fetus. FcγRIII may also contribute to antigen internalization
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antigen‐based rapid diagnostic tests (RDTs), or more sensitive nucleic 
acid amplification tests (PCR and LAMP). The presence of visible par‐
asites, parasite antigens, and/or plasmodial DNA in placental blood 
generally indicates an infection that is “active” at the time of delivery. 
Placental histopathology is frequently positive in cases in which pla‐
cental blood testing is negative; however, this is not merely an issue 
of sensitivity, but also reflects the timing and chronicity of infection. 
Visualization of malaria pigment (hemozoin) and fibrin on placental his‐
topathology indicates an infection that is chronic or one that occurred 
earlier in gestation but has since resolved, either spontaneously or due 
to drug treatment, including IPTp. Hence examination of the placenta 
offers a cumulative record of infections that occurred over the entire 
course of pregnancy, and when used in combination with sensitive 
PCR or LAMP testing of placental blood, provides the most complete 
picture of the infant's in utero exposure. It is not surprising, given the 
dynamic changes in the fetal immune system that occur during gesta‐
tion, that the timing and chronicity of antigen exposure might influence 
the fetal response. As discussed in detail below, a great deal of evi‐
dence indicates that chronic, active, and resolved placental infections 
may differ in their impact on fetal immune cell populations.
4  | PL ACENTAL MAL ARIA AND MATERNAL 
MICROCHIMERISM
In addition to foreign antigens, it is increasingly appreciated that sub‐
stantial numbers of maternal cells can enter the fetal circulation, even 
during normal pregnancy. These maternal cells establish a variable 
degree of microchimerism in the fetus that persists throughout life. 
As “non‐self,” these semi‐allogeneic maternal cells play an important 
role in the development of fetal tolerance to non‐inherited maternal 
alleles (NIMA) by inducing NIMA‐specific T regulatory cells (Tregs) that 
persist and remain functionally suppressive into adulthood.54 PM has 
been associated with higher levels of maternal microchimerism in cord 
blood, particularly when placental histopathology shows evidence of 
significant inflammation.48 The short‐ and long‐term consequences of 
this maternal microchimerism for infant immunity have not yet been 
fully explored, but increased induction of Tregs during gestation could 
lead to dampened pathogen‐specific immunity. It has also been noted 
that cord blood immune cell populations, including T‐cells, B‐cells, NK 
cells, and monocytes frequently include cells of maternal origin, which 
are particularly enriched among memory T‐cells.55 Although unproven, 
this raises the possibility that maternal‐origin immune effector cells 
may directly contribute to the fetal immune defense against malaria 
and other pathogens.
5  | THE FETAL IMMUNE SYSTEM: POISED 
TOWARD TOLER ANCE BUT RE ADY FOR 
AC TION
In order to understand the impact of malaria antigen exposure in 
utero, it is important to consider the ontology of the fetal immune 
system and the functional capabilities of its constituent cells, which 
evolve rapidly over the course of gestation. It has been known since 
Medawar's classic transplantation experiments of the 1950s that the 
fetus is uniquely disposed toward the induction of tolerance upon 
encounter with foreign antigens.56 This predisposition arises from 
the need for reciprocal immune tolerance between a mother and 
her semi‐allogeneic fetus, in order to avoid inflammatory responses 
to non‐self‐antigens that could trigger labor and threaten the preg‐
nancy. Much of our mechanistic understanding of fetal tolerance 
derives from murine models. However, fetal immune development 
differs markedly between humans and mice. Mice are profoundly 
immunodeficient at birth, with most T‐cell development occurring 
postnatally; for instance, murine T‐cells immigrate from the thymus 
only after birth. During human gestation, lymphocytes bearing phe‐
notypic markers of mature T‐cells can be detected in the fetal liver 
during week 10 of gestation,57 fetal thymic architecture is mature 
in appearance by week 14‐16, and T‐cell zones can be seen in the 
spleen during week 18. As in mice, human fetal T‐cells exhibit a pro‐
pensity toward tolerance, but it has become increasingly evident 
that under appropriate conditions, they are also capable of mounting 
a highly functional adaptive immune response.58‐61 Thus, rather than 
viewing the neonatal immune system as deficient or immature, it is 
appropriate to view it as a distinct entity with unique functional at‐
tributes that have evolved to meet the challenges of intrauterine life. 
As the fetus progresses toward term gestation, it must balance the 
competing demands of maternal tolerance with the need to mount 
effector T‐cell responses against pathogens encountered after birth.
At the time of birth, the vast majority of T‐cells in the human 
infant is naive in phenotype. While it had long been believed that 
the intrauterine environment is sterile, it is increasingly clear that 
this is not true in all cases, as demonstrated by a high prevalence 
of bacterial DNA and other microbial products in amniotic fluid.62 
Upon encounter with non‐self‐antigens, naive fetal CD4+ T‐cells 
preferentially differentiate into FoxP3+ regulatory T‐cells (Tregs), 
which suppress T‐cell activation and production of inflammatory cy‐
tokines.54 Tregs are particularly abundant in the human fetus during 
mid‐gestation.63 Fetal CD4 T‐cells have an intrinsic bias away from 
CD4 Th1 differentiation and inflammatory cytokine production in 
utero that is due in part to their epigenetic programming, including 
hypermethylation of IFNG locus.64 Priming of inflammatory T‐cell re‐
sponses is further inhibited by extrinsic factors, such as immaturity 
of fetal antigen‐presenting cell (APC) function and the presence of 
regulatory cell inhibition. Studies in both mice and humans suggest 
that during fetal life, APCs are relatively inefficient in their ability to 
prime adaptive immune responses.65‐67 This is likely related to their 
reduced expression of MHC II and costimulatory molecules and 
lower production of Th1‐polarizing cytokines, relative to their adult 
counterparts. In particular, neonatal dendritic cells (DCs) produce 
much lower quantities of IL‐12, the key cytokine required for Th1 
polarization, which has been linked to epigenetic regulation of its 
p35 subunit.65,67‐69 Elevated expression of arginase‐2 by fetal DCs 
has been shown to inhibit T‐cell production of TNFα.70 Monocytes 
in the fetus do not efficiently upregulate costimulatory and antigen 
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presentation machinery in response to IFNγ, as adult monocytes do. 
Lastly, in addition to suppressive FoxP3+ Tregs, other regulatory cell 
populations that are unique to the neonate, including CD71+ eryth‐
roid cells,71 myeloid‐derived suppressor cells,72 and B regulatory 
cells,73 have been reported to actively suppress T‐cell activation and 
cytokine production. Together, these mechanisms suppress inflam‐
mation in response to maternal antigens, but also present a barrier to 
mounting an effective adaptive T and B‐cell response to pathogens 
in the intrauterine environment.
As pregnancy progresses, the fetal immune system gradually 
evolves from one that is skewed toward tolerance to one that is 
poised to fight foreign pathogens. Over the past decade, it has be‐
come increasingly clear that the fetus is capable of mounting robust 
T‐cell responses under certain conditions. Fetal CD4 and CD8 T‐
cells that are reactive to maternal alloantigens can become activated 
and secrete Th1 cytokines (TNFα and IFNγ) that stimulate uterine 
contractions, contributing to preterm labor.28 Inflammation at the 
maternal‐fetal interface may be the initial signal which triggers the 
maturation of fetal DCs and subsequent activation of fetal T‐cells. 
Zhang et al demonstrated that human fetal CD4+ effector‐memory 
T‐cells that are capable of producing both Th1 and Th2 cytokines 
develop during healthy pregnancy, even in the absence of known 
intrauterine pathogen exposure.27 Among infants congenitally in‐
fected with viruses such as CMV, virus‐specific CD4 and CD8 cells 
that produce inflammatory cytokines can often be detected in the 
cord blood.58,61 Indeed, tetramer studies have demonstrated that in 
some fetuses, virus‐specific T‐cells are primed in utero by maternal 
influenza vaccination during pregnancy.74 These data make it clear 
that the essential machinery for generation of robust T‐cell response 
to pathogen‐derived antigens is present during fetal life. A better 
understanding of the conditions that foster the priming and devel‐
opment of functionally competent pathogen‐specific T‐cells will be 
of fundamental importance for the development of vaccines that are 
immunogenic in infancy.
6  | WHAT HAPPENS WHEN THE FETAL 
IMMUNE SYSTEM “SEES” MAL ARIA 
ANTIGENS?
6.1 | Cord blood cytokine production
A number of studies have identified differences in cytokine pro‐
duction by cord blood cells following stimulation with malaria anti‐
gens, mitogens, and TLR agonists. In aggregate, findings from these 
studies strongly indicate that exposure to malaria in utero alters the 
fetal immune system. However, many of these studies relied upon 
measurement of cytokines in culture supernatants following bulk 
stimulation, which precludes identification of the precise immune 
cell populations (eg αβ T‐cells, γδ T‐cells, NK cells, or APCs) and path‐
ways that are impacted by malaria exposure. Furthermore, substan‐
tial heterogeneity in cytokine production has been observed, both 
within and among cohorts. Malaria antigen stimulation has been 
shown to induce in vitro production of both Th1 and Th2 cytokines, 
with statistical differences between exposed and unexposed infants 
reported in a few but not all studies.11,17,21,75,76 Several studies have 
concluded that cytokine production by cord blood cells is modi‐
fied both by maternal gravidity and/or by the timing, duration, and 
chronicity of placental infection,16,17,75,77‐79 which may account for 
some of the observed variability among published findings. There 
is remarkably little published evidence for differences in cord blood 
plasma cytokine levels between exposed and unexposed infants, 
and our own data indicate that these differences are minimal (un‐
published observations). Natama et al reported that whole cord 
blood samples from placental malaria‐exposed infants exhibit lower 
spontaneous production of numerous pro‐inflammatory and anti‐in‐
flammatory cytokines, but higher production of many of the same 
cytokines in response to TLR7/8 stimulation, suggesting that the in‐
nate immune response is programmed in the fetus before birth.16 
However, as frequencies of individual cellular populations were not 
assessed, it is not clear whether the observed differences were due 
to an impact of malaria exposure on immune cell function, or merely 
reflect differing frequencies of constituent immune cell populations 
in the cord blood of exposed infants.16
6.2 | Fetal antigen presenting cells
Antigen‐presenting cells, including DCs and monocytes, are key or‐
chestrators of the immune response, influencing the development of 
both immunological memory and tolerance. DCs play a paramount 
role in the initiation and regulation of adaptive immune responses 
through priming of antigen‐specific CD4+ T‐cells. Plasmodium falcipa-
rum has been demonstrated to modulate dendritic cell function and 
maturation both in vivo and in vitro, leading to decreased expression 
of maturation, cell adhesion and costimulatory markers.77,80 The re‐
sulting immature, or “tolerized” DCs have a diminished capacity to 
activate effector T‐cells.80 However, this effect appears to require 
intact parasite‐infected erythrocytes, which are not frequently ob‐
served in fetal blood.80 It is therefore unclear whether the tolerizing 
impact of Plasmodium on DCs is relevant in the fetus, in whom DCs 
already have an intrinsically higher threshold for activation. Another 
question that merits further investigation is whether distinct antigen 
presenting cell populations may be important during fetal life. For 
instance, γδ T‐cells are particularly abundant in the fetus and pos‐
sess robust antigen presentation capabilities upon activation,81,82 
suggesting that they could play a role in the induction of adaptive 
immune responses in utero.
The impact of malaria antigen exposure on professional APCs 
in the fetus has been directly assessed in only a few studies. We 
and others have observed that frequencies of myeloid DCs (mDCs), 
but not plasmacytoid DCs, are markedly elevated in the cord blood 
of malaria‐exposed infants.83,84 The functional competence of 
mDCs and other APCs in the uptake, processing, and presentation 
of malaria antigens to T‐cells in utero is not fully understood. Data 
regarding the degree to which fetal mDC mature and upregulate co‐
stimulatory molecules in response to PM are somewhat mixed, and 
suggest that the duration or persistence of parasite exposure may 
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play a modulatory role. For instance, it has been reported that in‐
fants born to mothers with active PM do not exhibit significant mDC 
upregulation of MHC II,84 while those with chronic infection upreg‐
ulate MHC II but not CD86 on cord blood mDCs.85 Likewise, fetal 
monocytes appear to upregulate MHC II in past/resolved PM but 
not in active infection.77 In the latter study, co‐culture of cord blood 
mononuclear cells with P. falciparum‐infected RBCs dramatically 
reduced both MHC I and II expression on monocytes from infants 
with active PM, while having no impact in infants with past or no 
infection. Together, these data suggest that the sustained presence 
of parasites inhibits infant APC maturation through mechanisms 
that remain unclear. Furthermore, they support the notion that the 
threshold for activation and maturation of fetal APCs is high, and ex‐
posure to transplacentally transferred antigen may be insufficient to 
drive costimulatory signals needed for efficient antigen presentation 
function in utero. Further investigation of phenotypic and functional 
features of infant DCs is warranted, given their critical role in prim‐
ing of neonatal vaccine responses.
6.3 | Regulatory fetal T‐cells
Several studies have specifically addressed the hypothesis that fetal 
exposure to malaria antigens induces the development of regulatory 
CD4 T‐cells, a mechanism by which the fetus could actively acquire 
peripheral tolerance to malarial antigens.79 Two major populations 
of regulatory CD4 T‐cells are induced by malaria and play potentially 
important roles in its immunopathogenesis: FoxP3+ Treg cells, and 
IL10‐producing CD4 cells of the Tr1 phenotype. One of the earliest 
studies to hypothesize a role for regulatory T‐cell induction in utero 
reported that frequencies of Tregs are higher among infants born to 
women with PM.79 However, this study was performed before the 
role of FoxP3 was appreciated, and defined Tregs based on elevated 
expression of the high affinity IL2 receptor alpha chain (CD25hi CD4 
T‐cells), which might include effector T‐cells that express CD25 tran‐
siently upon activation. Subsequent studies that used a more com‐
prehensive set of Treg markers have failed to replicate this association 
of Treg frequencies with PM.
76,83,86 Nonetheless, depletion of cord 
blood Tregs has been shown to augment the malaria‐specific IFNγ 
production in vitro and to abrogate production of the immunoregu‐
latory cytokine IL‐10,76,79,87 indicating that fetal Tregs are function‐
ally suppressive. Flanagan et al found that cord blood frequencies 
of FoxP3+ Tregs do not differ ex vivo, but differentiation of T‐cells 
into Tregs following in vitro antigen stimulation is higher among in‐
fants born to women with PM.86 Another factor that may influence 
induction of FoxP3+ Tregs is the timing of malaria exposure relative 
to fetal immune development. In a longitudinal study of mother‐in‐
fant pairs followed from 12‐20 weeks gestation, we found that cord 
blood FoxP3+ Treg frequencies did not differ between those with and 
without histopathologic evidence of PM; however, Tregs were mod‐
estly elevated in infants whose mothers were already parasitemic 
at enrollment into the study.83 This could suggest that first or early 
second trimester malaria exposure is more prone to induce Treg dif‐
ferentiation, whereas infections occurring closer to term may not 
have the same effect. Such a model would be consistent with the 
demonstrated propensity for naive T‐cells in the mid‐gestation fetus 
to differentiate into FoxP3+ Tregs upon foreign antigen exposure.
54
IL10‐producing Tr1 cells, which can also suppress malaria‐spe‐
cific T‐cell proliferation, dominate the malaria‐specific CD4 T‐cell 
response in heavily exposed children.88 Tr1 cells frequently co‐pro‐
duce IFNγ along with IL10 and express the canonical Th1 transcrip‐
tion factor T‐bet. In studies of malaria‐exposed Gabonese infants, 
CD4 T‐cells that produce IL10 in response to stimulation with par‐
asitized red blood cells were non‐significantly elevated in the cord 
blood of infants with active (but not past/resolved) PM, and anti‐
body blockade of IL10‐ enhanced malaria‐specific CD4 T‐cell IFNγ 
production in these infants.77,79 However, among infants in a recent 
maternal chemoprevention trial, we did not observe IL10 production 
by CD4 T‐cells, even in those with active PM.18 These discrepant 
findings could potentially be explained by the fact that participants 
in the latter trial received at least three doses of IPTp during preg‐
nancy, which may have cleared placental parasites. It is plausible that 
IL10 production by CD4 cells in utero modulates fetal immunity but 
is abrogated upon parasite clearance, making this phenomenon chal‐
lenging to study in the setting of widespread IPTp implementation.
6.4 | Malaria‐specific effector T‐cells
We have recently shown that some infants develop highly functional 
malaria‐specific CD4 and CD8 T‐cells following in utero malaria ex‐
posure,18 adding to the growing body of evidence that fetal T‐cells, 
under appropriate circumstances, can be primed and differentiate into 
competent effector cells prior to birth.58‐60 In Ugandan infants born to 
mothers with active PM, we observed markedly elevated frequencies 
of effector‐memory CD4 T‐cells (TEM) in cord blood, as well as higher 
frequencies of CD4 T‐cells expressing Ki67, a marker for in vivo pro‐
liferation. Cord blood CD4 TEM cells were confirmed by fluorescence 
in situ hybridization (FISH) of X and Y chromosomes to be of fetal, not 
maternal, origin.18 These findings strongly indicate that fetal T‐cells 
of malaria‐exposed infants undergo antigen‐driven expansion prior 
to birth. The fetal CD4 TEM population was comprised of phenotypi‐
cally diverse T‐helper populations, including Th1, Th2, and Treg subsets; 
transcription factor expression was likewise heterogeneous, with sig‐
nificant expression of factors associated with Th1 (Prdm1, Tbx21, and 
BATF), Th2 (Gata3), and Th17 (RoRγT) cells.18 Expansion of CD4 TEM 
cells was also seen, though to a lesser degree, in infants with past/re‐
solved PM. Notably, CD4 and CD8 T‐cells in malaria‐exposed infants 
were highly functional, demonstrating both robust malaria‐specific pro‐
liferation and production of inflammatory cytokines. Antigen‐specific 
proliferation was observed in response to both whole parasite antigen 
(P. falciparum schizont extract) and the immunodominant MSP1 blood 
stage antigen.18 The frequency of proliferating cells was highest among 
infants born to mothers with active PM, but those with past/resolved 
infection also demonstrated greater proliferation, in both the CD8 and 
CD4 T‐cell compartment, than unexposed infants. This proliferation 
was abrogated by MHC I and II blockade, respectively, confirming that 
this response is TCR‐dependent. Higher frequencies of CD4 and CD8 
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T‐cells producing TNFα and IFNγ following in vitro mitogen stimula‐
tion were also seen in exposed infants (again, with stronger responses 
in those with active than past/resolved infection), contrasting with the 
findings of Brustoski et al, who reported T‐cell IFNγ production to be 
higher in infants with resolved infection.77,79 IL10 production by fetal 
T‐cells was notably absent among infants in our study.
The most striking finding from this study is that malaria‐specific 
CD4+ T‐cell proliferation correlated with prospective protection from 
both P. falciparum infection and symptomatic malaria during the first 
2 years of life.18 This is somewhat surprising, as a protective role for 
CD4 T‐cells has been difficult to establish, even in older children with 
greater immunological maturity.89 While the association between CD4 
responses and protection certainly requires confirmation in future 
prospective studies, it raises the intriguing prospect that functional 
malaria‐specific T‐cell responses can be generated in utero and afford 
protection against pathogen exposure in early childhood.
Why might the fetus mount a protective T‐cell response, when 
it is not clear that young children can? One potential reason is that 
postnatal malaria infection results in an extremely high antigen 
burden, which triggers numerous immunoregulatory mechanisms 
including skewing of the CD4 response toward a Tr1 phenotype 
characterized by production of IL10.88,89 Such regulatory responses 
interfere with the generation of functional, durable, proliferation‐
competent T‐cell responses.88 In contrast, PM results in a low dose 
exposure to blood stage antigens, which have been shown in other 
settings to prime robust, highly proliferative CD4 T‐cell responses 
and induce sterilizing immunity.90,91
Further research is needed to determine how malaria exposure 
enables fetal T‐cells to overcome the general bias away from inflam‐
mation in utero, and this will likely require a better understanding of 
the antigen‐presenting capabilities of the fetus. In this regard, it is 
notable that not only CD4 but also CD8 T‐cells from exposed infants 
exhibit malaria‐specific responses. Priming of CD8 cells in utero would 
presumably require MHC I cross‐presentation of exogenous malaria 
antigens taken up by fetal antigen presenting cells, which may be facil‐
itated by transplacental transfer of malaria antigen in the form of im‐
mune complexes.19,39 As TNFα and IFNγ secretion by fetal T‐cells can 
stimulate uterine contractions, contributing to preterm labor,60 this in‐
flammatory bias in the malaria‐specific fetal T‐cell response could help 
to explain the elevated risk of prematurity seen with PM.
6.5 | Gamma Delta (γδ) T‐cells
Gamma delta (γδ) T‐cells are the first T‐cells to develop in the human 
fetus, and they comprise 2%‐5% of circulating T lymphocytes in 
adults. They exhibit rapid, innate‐like effector function that is not 
dependent on prior antigen exposure nor on priming by DCs, which 
are functionally immature in the fetus. Therefore, γδ T‐cells are in 
many ways uniquely suited to protection of the fetus and infant. 
Indeed, in murine models of parasitic infection, γδ T‐cells are re‐
quired for protection in the young, but not in mature animals.92 
Moreover, γδ T‐cells are remarkably conserved across vertebrate 
species and they are the first T‐cells to develop in all species studied 
to date. It has been hypothesized that the primary selective advan‐
tage driving this conservation is their role in neonatal protection.82
Like conventional αβ T‐cells, γδ T‐cells recognize antigen 
through a T‐cell receptor (TCR), which is generated by recombina‐
tion of Vγ and Vδ gene segments. A single pairing consisting of δ2 
and γ9 chains accounts for 50%‐75% of all γδ T‐cells in adult pe‐
ripheral blood. Vγ9Vδ2 T‐cells recognize non‐peptide phosphoan‐
tigens that are abundantly produced by the Plasmodium apicoplast. 
Phosphoantigen recognition by Vγ9Vδ2 cells is TCR‐dependent 
but does not require processing or presentation by professional 
APCs. Instead, phosphoantigens bind the ubiquitously expressed 
molecule butyrophilin 3A1, inducing a conformational shift that 
enables recognition by the γδ TCR.93,94 As a result, malaria anti‐
gens stimulate a marked proliferative expansion of Vγ9Vδ2 cells 
both in vitro and in vivo (comprising up to 30% of peripheral blood 
T‐cells).95 Vγ9Vδ2 cells exhibit intrinsic reactivity to malaria anti‐
gens and can act as innate‐like effectors, rapidly degranulating and 
producing inflammatory cytokines such as IFNγ and TNFα upon 
phosphoantigen stimulation, even in malaria‐naive individuals. 
Activated Vγ9Vδ2 cells inhibit parasite growth and kill extracel‐
lular merozoites via release of granulysin,96 and in human clinical 
trials they have been associated with protection from malaria.97,98 
However, in settings of repeated malaria exposure, chronic anti‐
genemia results in the eventual loss and dysfunction of circulating 
Vγ9Vδ2 cells.99
At mid‐gestation, fetal blood is highly enriched for Vγ9Vδ2 cells 
that can be rapidly activated to produce IFNγ and granzyme A upon 
stimulation.100 This “fetal wave” of Vγ9Vδ2 T‐cell development sup‐
plies the infant with innate‐like T‐cells capable of rapid activation and 
effector function. Intriguingly, mid‐gestation Vγ9Vδ2 T‐cells exhibit a 
markedly restricted TCR repertoire, with almost half of CDR3γ9 se‐
quences encoded by the germline Vγ9‐Jγ1.2 sequence100 that is known 
to react to malaria‐derived phosphoantigens.101 The Vγ9Vδ2 popula‐
tion steadily declines as a proportion of circulating lymphocytes be‐
tween 20 and 40 weeks gestation.100,102 However, we have found that 
infants born to mothers with PM have elevated frequencies of Vγ9Vδ2 
cells in cord blood (unpublished data), and others have observed that 
cord blood Vγ9Vδ2 T‐cells are preferentially activated, produce more 
IFNγ,103 and exhibit greater memory differentiation104 following in 
utero malaria exposure. While many questions remain, it is attractive 
to hypothesize that γδ T‐cells equip the infant with an army of ready‐
made innate effector cells that protect against fatal malaria during 
early childhood, while adaptive immunity develops.
6.6 | NK Cells and Other Innate Lymphocytes
The relationship between prenatal malaria exposure and other in‐
nate lymphocyte populations, including NK cells and other more re‐
cently described ILCs, has not been well studied. At least one study 
observed expansion of CD56dimCD16+ NK cells in malaria‐exposed 
neonates at birth,105 but the frequencies of other NK populations 
and their potential antimalarial functions have not been assessed. 
Despite their immaturity, neonatal NK cells are highly responsive to 
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immune complexes47 and exhibit robust antibody‐dependent func‐
tions including IFNγ production and degranulation, which suggests 
that they could be an important antimalarial effector population in 
utero and in the newborn. Further studies of their role in the fetal 
and infant immune response are warranted.
6.7 | Malaria‐specific Antibodies
Transplacental transfer of maternal‐origin antibodies is essential for pro‐
tecting the infant from pathogens encountered during the initial months 
of life. During pregnancy, maternal IgG antibodies are transferred to the 
fetus via an active transport mechanism mediated by FcRn, the neona‐
tal Fc receptor, which selectively transfers IgG but not other antibody 
classes. The amount of antibody transported to the infant is influenced 
by multiple factors including IgG subclass, glycosylation, gestational age, 
and total maternal IgG concentration, as well as pathologic states includ‐
ing maternal HIV and placental infection (recently reviewed by Wilcox et 
al46). Several Fc region characteristics, including secondary glycan struc‐
tures,47 have been shown to modulate the efficiency of transplacental 
IgG transfer, which can vary across pathogens and even across antigen 
specificities within an individual.106,107 Overall, transfer efficiency is 
highest for the IgG1 subclass, followed by IgG4, IgG3, and IgG2. FcRn 
is expressed on syncytiotrophoblasT‐cells beginning at around 13 weeks 
gestation.108 Transfer of IgG increases exponentially as pregnancy pro‐
gresses, with a sharp increase in IgG transfer during the final month of a 
term pregnancy.46,108 In the full‐term neonate, IgG levels often exceed 
those of the mother. While term infants have higher absolute levels of 
maternal IgG than preterm infants, the repertoire of epitope specificities 
is largely similar between premature and full‐term infants.107
Chronic maternal infections including HIV and malaria have been 
associated with reduced transfer of IgG across the placenta, which 
appears to vary by antigen specificity and subclass, with relative pres‐
ervation of IgG3 transfer efficiency.109 However, most studies exam‐
ining the impact of PM on antibody transfer have focused on the IgG 
transfer ratio rather than absolute IgG levels in cord blood. This is a 
key point because, similar to HIV, malaria can cause maternal hyperga‐
mmaglobulinemia, and FcRn‐mediated transport saturates in the set‐
ting of high total IgG levels. Therefore, a lower proportional transfer 
of maternal malaria‐specific antibodies does not necessarily translate 
into low absolute antibody levels in the fetus. As reviewed in detail 
elsewhere,110 there are conflicting data regarding the impact of PM 
on the transfer of antibodies against both malaria and other specific‐
ities, with some studies showing a reduction in absolute or relative 
IgG transfer, and others showing no impact. In a recent randomized 
clinical trial of intensive malaria chemoprevention during pregnancy, 
there was no impact on cord blood levels of antibodies to 19 malaria 
antigens, despite a dramatic reduction in maternal and PM.111
In addition to antibodies transferred from the mother, the fetus 
is capable of producing its own malaria‐specific antibodies in utero. 
In several studies, malaria‐specific antibodies of the IgM class (which 
cannot cross the placenta) have been detected in the cord blood 
of malaria‐exposed infants, suggesting in utero priming of fetal B‐
cells.19‐21 Tassi Yunga et al reported that malaria‐specific IgM can be 
detected as early as 22 weeks gestation, and malaria‐specific fetal 
B‐cells can undergo class‐switching to IgG prior to delivery.19 This 
raises the possibility that fetal B‐cells could be sensitized by mater‐
nal malaria vaccination, as has been reported to occur with tetanus 
and influenza vaccination.74,112
The importance of both maternal‐origin and fetal‐origin antibod‐
ies in protection from malaria following birth remains unclear. It has 
been widely maintained that malaria‐specific antibodies of mater‐
nal origin play an important role in protecting the infant during the 
early months of life. However, a thorough review of the published 
literature on this topic concluded that there is scant evidence to 
support such a protective role, and that instead most evidence sug‐
gests that malaria‐specific IgG in cord blood represents a biomarker 
of maternal malaria exposure.113 However, this analysis was based 
on measurement of total IgG levels and did not take into account 
more recent evidence indicating that cytophilic IgG subclasses, par‐
ticularly IgG3, may play a more important role in protection, likely 
due to their ability to fix complement and/or engage of FcR‐bearing 
lymphocytes and phagocytes.114 Future studies should carefully ad‐
dress the role of antibody subclass, glycosylation, and FcR‐mediated 
engagement of cellular immunity in infant protection from malaria.
7  | SE X DIFFERENCES IN THE INFANT 
IMMUNE RESPONSE
The immune response to many infections differs by sex, both in chil‐
dren and in adults.115,116 In general, females exhibit more robust innate 
and adaptive immunity than males, including higher postvaccination 
antibody titers, more rapid antigen clearance, and lower levels of 
chronic viremia. However, females are more susceptible to autoim‐
mune and inflammatory disease and have higher rates of postvaccina‐
tion adverse reactions, both local and systemic.115 To date, few studies 
have examined sex differences in malaria susceptibility, clinical out‐
comes, or immunity. Limited but intriguing data suggest a more inflam‐
matory response to malaria in females. For instance, a retrospective 
analysis of data from phase III trials of the leading malaria candidate 
vaccine RTS,S/AS01 found that vaccination in infancy was associ‐
ated with a highly significant increase in all‐cause mortality among 
female but not male children.117 Furthermore, there was a tendency 
toward an increased risk of fatal malaria in females, but not males.117 
These findings echo the increased vaccine‐associated mortality seen 
in females following introduction of the high‐dose measles vaccine 
(HTMV), when all‐cause mortality among girls (but not boys) doubled, 
leading to its eventual withdrawal from the market.118 Additionally, in 
a recent clinical trial, the impact of maternal IPTp on infant malaria 
outcomes appeared to be modified by sex, with female but not male 
infants showing increased susceptibility to malaria during the first two 
years of life.111 The biologic underpinnings of these sex difference in 
malaria outcomes have not been identified.
Even as newborns, boys and girls differ in their cord blood im‐
mune cell composition, indicating that sexual dimorphism in the im‐
mune response emerges during fetal life. In a recent birth cohort 
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study of Ugandan infants, we found that male newborns have sig‐
nificantly higher frequencies of regulatory FoxP3+ CD4 cells (Tregs) 
in cord blood.119 As most infants in this cohort were exposed to ma‐
laria in utero, this could suggest an enhanced propensity for antigen‐
driven Treg differentiation in males. However, another recent study 
also found higher Treg frequencies in males at birth, in the absence of 
known pathogen exposure,120 suggesting an intrinsic male propen‐
sity toward regulatory differentiation that is independent of patho‐
gen exposure. CD5+ naive/immature B‐cell frequencies are also 
higher in male newborns, and correlate with levels of dihydrotestos‐
terone at birth, suggesting a hormonal influence on immune devel‐
opment.121 Hormonal differences between males and females first 
emerge during gestation, with testosterone produced by male testes 
as early as the tenth gestational week.122 In addition to potential 
hormonal effects, genes encoded by sex chromosomes may contrib‐
ute to a sexually dimorphic immune response. Many genes critical 
for immune function and immunoregulation are encoded by the X 
chromosome (eg those encoding FoxP3, TLR7, TLR9, and IRAK), and 
it is estimated that 15% of the 1000 human X chromosome genes 
that lack a homologue on the Y chromosome may escape X inactiva‐
tion, making them subject to gene dosage effects.123 It is critical that 
the potential for sex‐based differences receive careful attention in 
future studies of the immune response to malaria, both in naturally 
exposed populations and in malaria vaccine trials.
8  | DOES IN UTERO  ANTIGEN E XPOSURE 
IMPAC T THE DE VELOPMENT OF IMMUNIT Y 
TO MAL ARIA IN INFANCY?
The most important question regarding in utero malaria exposure is 
whether it has an impact – good or bad – on the development of im‐
munity during childhood. It is biologically plausible that fetal expo‐
sure to malaria during a critical developmental window could induce 
tolerance, mediated by regulatory T‐cells or other mechanisms that 
might hinder the priming of malaria‐specific B and T‐cell responses 
postnatally. Indeed, there is precedent for such an effect with hel‐
minths, as maternal filarial infection is associated with a 13‐fold in‐
crease in the risk of filaria in offspring.124 Consistent with this model, 
several studies have reported that infants born to women with PM 
are themselves at higher risk of malaria during early life.8‐11,125,126 
However, this association has not been observed in all cohorts,127‐129 
and indeed one study found that infants of primagravidas with PM 
actually have a lower risk of parasitemia during infancy.7
A parsimonious explanation for the repeated observation of higher 
infant malaria risk following in utero exposure is that these studies are 
confounded by variability in exposure. In other words, women with 
P. falciparum infections during pregnancy have greater environmental 
exposure to infected mosquitoes, and their infants would share this 
higher exposure risk. Such confounding can be circumvented by ex‐
amining infant malaria outcomes in the setting of a randomized inter‐
vention that prevents malaria during pregnancy, and thus “uncouples” 
maternal and infant exposure. A recent trial in which women were 
randomized at 12‐20 weeks gestation to receive standard IPTp vs in‐
tensive chemoprophylaxis found that despite a dramatic reduction in 
PM, infants whose mothers received the intensified chemoprevention 
regimen (monthly DP) actually had a higher incidence of clinical ma‐
laria episodes and parasitemia during the first 2 years of life, and a 
shorter time to first malaria episode, than those receiving standard 
IPTp.111 Therefore, in this trial, prenatal exposure to malaria appeared 
to reduce the infant's risk of malaria after birth.
How can these divergent findings be reconciled? One possible ex‐
planation relates to the gestational timing of fetal exposure. The im‐
pact of in utero antigen exposure may differ between early and late 
pregnancy, leading to tolerance with early exposure and priming of 
adaptive malaria‐specific T and B‐cells with late gestation exposure. 
Initiation of intensive maternal chemoprevention during the second 
trimester, as in the trial cited above, would reduce fetal exposure late 
in pregnancy but not during the first and early second trimester, when 
fetal T‐cells are most prone toward tolerance. If true, chemopreven‐
tive interventions could have the paradoxical effect of pre‐empting 
malaria‐specific fetal T and B‐cell responses that might contribute to 
postnatal protection from malaria.18 The timing of fetal malaria expo‐
sure will be a critical variable to consider in future studies of inter‐
ventions to PM, which should include prospective clinical follow‐up 
of infants with detailed analysis of their cellular and humoral immune 
responses. At present, the long‐term clinical impact of in utero expo‐
sure to malaria remains an open question.
Beyond its impact on malaria‐specific immunity, it has been hy‐
pothesized that in utero malaria exposure could have a global toler‐
izing impact on infant immunity, resulting in heightened vulnerability 
to non‐malarial pathogens. Specifically, malaria‐induced tolerization of 
fetal APCs and/or innate lymphocyte populations could have broad 
effects on the infant's immune responsiveness to infection and vac‐
cination. To date, limited clinical data support this notion.15 Future 
randomized trials designed to reduce in utero malaria exposure could 
provide a useful framework for empirically testing this hypothesis.
9  | CONCLUDING REMARKS
Despite the incomplete and somewhat conflicting data currently 
available, there is strong evidence that PM impacts the fetal immune 
system. In a high proportion of affected pregnancies, the fetus is 
directly exposed in utero to malaria antigens that cross the placenta, 
yet there appears to be substantial heterogeneity in how the infant 
responds. In some infants, fetal exposure to malaria may result in T‐
cell tolerance, providing a plausible biological mechanism by which 
PM may increase the risk of malaria during childhood. However, 
identification of malaria‐specific antibodies and T‐cells in cord blood 
raises the intriguing prospect that functional and protective malaria‐
specific immune responses can be generated in utero, and may even 
contribute to postnatal protection from malaria.
In recent years, efforts to prevent PM have gained substantial trac‐
tion. These efforts include trials of new artemisinin‐based regimens 
for IPTp and implementation of vector‐targeted interventions, such as 
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insecticide‐treated bed nets and pesticide spraying. Nonetheless, fewer 
than half of pregnant women in regions at risk sleep under an insecticide‐
treated net or receive IPTp in accordance with current WHO recomen‐
dations.6 Innovative approaches are needed to reduce the enormous 
burden of pregnancy‐associated malaria on maternal and child health. 
Before new malaria control interventions are widely implemented, how‐
ever, questions about their potential downstream consequences for the 
fetus must be carefully considered, as their impact may be paradoxical. 
For instance, studies performed in Mozambique following a dramatic 
decline in local malaria transmission intensity found that PM was as‐
sociated with increased parasitemia levels in both peripheral and pla‐
cental blood, and a greater adverse impact on infant birth weight, than 
in historical controls.130 Thus, while the prevalence of PM declined, its 
harmful impact on the fetus (and potentially fetal antigen exposure) in‐
creased. On the other hand, if transplacental transfer of malaria antigens 
occurs largely in the form of immune complexes, waning population im‐
munity may result in lower maternal levels of malaria‐specific IgG, and 
hence less antigen transfer and fetal exposure. In light of this complexity, 
the possible implications of future control measures on in utero malaria 
exposure should receive careful consideration prior to implementation.
It is essential that future studies further define the factors – which 
may include the timing, duration, and extent of placental infection and 
fetal antigen exposure ‐ that influence the fetal immune response. 
Very little is currently known about the mechanisms by which PM re‐
sults in fetal growth restriction and preterm birth, including the poten‐
tial role of maternal and infant immune responses. Another important 
area for future investigation is the role and functional capabilities of 
various antigen presenting cell populations in the fetus, and how they 
might be manipulated to engender adaptive immune responses that 
do not result in excess inflammation that threatens continuation of 
the pregnancy. Additionally, the role of innate and semi‐innate lym‐
phocyte populations, including NK and γδ T‐cells, in malaria‐exposed 
infants has received insufficient research attention. By harnessing the 
specificity of maternal‐origin antibodies, these FcR‐expressing effec‐
tor lymphocyte populations could provide a valuable first line of de‐
fense in the fetus and neonate, prior to the development of robust 
adaptive immunity. Finally, future studies of infant immunity should 
pay careful heed to sex differences in both the innate and adaptive 
immune response to malaria in the infant.
The past decade has seen great progress toward reducing malaria 
mortality and addressing its harmful impact on pregnancy. As we look 
hopefully toward an era of malaria vaccination, it is time to address a 
refined set of questions regarding the impact of prenatal malaria expo‐
sure on individual fetal immune cell populations and molecular path‐
ways. Ultimately, questions regarding the clinical impact of in utero 
malaria exposure, and interventions to prevent it, must be answered 
empirically through careful studies of the infant immune response to 
vaccination and natural pathogen exposure in infancy.
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